Earlier in this series I wrote about the Alec Smith law — Minnesota's rescue of one medicine, insulin, for the people who were dying without it. That law treats a symptom. This is the piece about the attempt to treat the disease: the fact that Americans pay two, three, ten times what people in other wealthy countries pay for the exact same drugs, made by the same companies, and that no one in our system has ever really had the authority to say no, that price is too high.
Minnesota created a body designed to say exactly that.
What the board is
Minn. Stat. § 62J.87 establishes the Prescription Drug Affordability Board — a nine-member panel of experts in pharmaceutical and health-care economics, appointed by the governor and legislative leaders, and pointedly walled off from the industry: a member "must not be an employee of, a board member of, or a consultant to a manufacturer" or a pharmacy-benefit manager. Its stated job is to "protect consumers, state and local governments, health plan companies, providers, pharmacies, and other health care system stakeholders from unaffordable costs of certain prescription drugs."
Here's how it works. Manufacturers already have to report price information to the state; that data flows to the board (§ 62J.90), which then decides which high-cost drugs to put through an affordability review — a formal study of whether a drug's cost is causing affordability problems for Minnesotans. And for the drugs it finds unaffordable, the board is empowered to set an upper payment limit — effectively a cap on what can be paid for that drug across the state. That last power is the radical part. It's not disclosure, not a nudge, not a voluntary program. It's a state body with the authority to look at a $15,000 drug and say: in Minnesota, the payment for this is capped here.
Tellingly, the Attorney General is written into the law as the board's lawyer, and the statute includes a severability clause (§ 62J.95) — the legislative equivalent of bracing for impact. You don't add "if a court strikes down part of this, the rest survives" unless you fully expect to be sued.
Why it matters
Because the drug-pricing problem is structural, and one-drug rescues can't keep up with it. For every insulin there are a hundred other medicines — cancer drugs, rare-disease treatments, specialty biologics — priced at levels that bankrupt families and blow holes in the state's own budget as a purchaser of health care through Medical Assistance and public employees. The affordability board is an attempt to build a repeatable process for confronting those prices, instead of passing a new emergency law every time a single drug makes headlines. Minnesota is one of a growing set of states — Colorado, Maryland, Washington, and others — building these boards precisely because the federal government's power to negotiate drug prices, even after recent expansion, reaches only a narrow slice of Medicare and leaves everyone else exposed.
The honest hard part
I'll give you the real objections, because they're not nothing. First, the industry's argument: cap what's paid for a drug and you may affect whether it's stocked and available — a payment limit is not the same as a supply guarantee, and there are genuine questions about how an upper payment limit interacts with national supply chains and whether a manufacturer simply declines to make a drug available at the capped amount. That's a real design challenge, not a talking point. Second, the constitutional and legal fights are serious and unsettled — pharma is challenging these boards around the country on theories ranging from interstate-commerce limits to preemption, and Minnesota's severability clause tells you the state knows the upper-payment-limit power in particular will be tested in court. This is frontier policy, and frontiers are contested.
But the alternative — a system where no one has the authority to question any price, ever — is how we got here. Someone has to be able to say a price is unaffordable and act on it. The board is Minnesota's answer, and it deserves to be defended and refined, not abandoned at the first lawsuit.
What we can do
Let the board actually use its teeth. A review process that never results in an upper payment limit is just another study group. The board should be resourced and backed to complete real affordability reviews and set limits where the facts warrant — and the Attorney General should defend those decisions.
Design the payment limit to protect access. The strongest objection is the supply question. Build the upper-payment-limit process with safeguards and monitoring so a cap lowers cost without pushing a needed drug out of Minnesota pharmacies.
Coordinate with the other states. Minnesota isn't alone, and pharma's strategy is to pick the boards off one at a time in court. A coalition of drug-affordability-board states, sharing legal defense and pricing data, is far harder to beat than any one state by itself — the states'-strength-in-numbers version of the federalism argument running through this series.
The insulin law saved one medicine by name. The affordability board is the attempt to build the machinery to do it for all of them. That's a big, contested idea — and exactly the kind of thing a state should try when the country won't.
First the facts. Then the fix.
Sources
Minn. Stat. §§ 62J.87–62J.95, enacted 2023 (2023 Minn. Laws ch. 57, art. 2), verified against raw text at revisor.mn.gov: the establishment, purpose ("protect consumers... from unaffordable costs of certain prescription drugs"), nine-member composition, and industry-conflict prohibitions of the Prescription Drug Affordability Board, with the Attorney General directed to provide legal services to the board (§ 62J.87); the flow of manufacturer price information to the board and the decision to conduct a cost/affordability review (§ 62J.90, as further affected by 2026 Minn. Laws ch. 124); and the severability clause covering §§ 62J.85–62J.94 (§ 62J.95). The board's authority to set upper payment limits for drugs found unaffordable is established by the balance of the chapter (§§ 62J.91–62J.94). Several other states (including Colorado, Maryland, and Washington) have created similar prescription-drug affordability boards; the federal Medicare drug-price-negotiation authority reaches only a limited set of drugs. Cross-reference to this series' article on the Alec Smith Insulin Affordability Act.
The precise upper-payment-limit procedure and standards in §§ 62J.91–62J.94, and the status of any litigation challenging Minnesota's board specifically, were not quoted verbatim or enumerated this pass and are described in general terms; the national litigation against drug-affordability boards is characterized generally. Corrections: campaign@madgettformn.com.